NASDAQ:LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.'s revenue grew 60.2% in fiscal 2025 to $49.8M while operating margin rose to −98.2%. Free cash flow was −$67.9M, −136.2% of revenue, and the diluted share count rose 13.4%.Summary generated from Lexicon Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$49.8M
Revenue growth+60.2%
Revenue, 5-yr CAGR+15.7%
Gross margin99.4%
Operating margin−98.2%
Net margin−101.1%
ROIC−25.2%
Return on equity−39.7%
Debt / equity0.50
Free cash flow−$67.9M
FCF margin−136.2%
Share count change+13.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 31 | 50 |
| Operating income | −87 | −101 | −172 | −197 | −49 |
| Net income | −88 | −102 | −177 | −200 | −50 |
| Free cash flow | −88 | −90 | −162 | −180 | −68 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Jun 4, 2026 - 4Insider transaction report
Jun 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - 8-KEntry into a material agreement
May 6, 2026 - 8-KEntry into a material agreement
Apr 30, 2026